USA – FDA says widening probe on generic drug impurities

The U.S. Food and Drugs Administration said on Wednesday it was expanding its investigation into impurities in U.S. generic drugs beyond a class of medicines for high blood pressure known as angiotensin II receptor blockers (ARBs).

The agency did not specify which types of additional drugs it was looking at, but said it was testing samples of other medicines with similar manufacturing processes to those in which concerning impurities have been discovered.

Since last summer, the FDA has been conducting a major investigation to address the presence of certain impurities that could cause cancer in ARBs such as valsartan, the generic of Novartis’ Diovan. Some generic ARBs, such as valsartan and irbesartan, have been recalled…